Canonical: https://neurodiversity.gklijs.tech/i/2d1893854279

# Teva Pharmaceutical R&D Day 2026: First-in-Class Drugs for Tourette Syndrome, Celiac Disease, and IBD Scarring

Tech Times

12 November 2026 (2026-11-12)

Teva Pharmaceuticals announced three first-in-class drug candidates targeting previously untreatable aspects of Tourette syndrome, celiac disease, and inflammatory bowel disease scarring, marking a shift toward innovation for the company. Ecopipam, a selective D1/D5 dopamine receptor antagonist for Tourette syndrome, demonstrated significant tic reduction in clinical trials and received FDA Priority Review and Orphan Drug Designation. These developments highlight Teva's transformation into a biopharmaceutical innovator with a robust pipeline of novel therapies.

[Read at Tech Times](<https://www.techtimes.com/articles/330495/20261111/teva-pharmaceutical-rd-day-2026-first-class-drugs-tourette-syndrome-celiac-disease-ibd.htm>)

All articles from [12 November 2026](</2026/11/12>). Summaries are AI-generated and may contain errors; the linked article is the authority.

## Get this news by email

Daily or as a weekly roundup in your inbox. You confirm your address first; every email has an unsubscribe link. For another topic or language, use the [subscribe page](</subscribe>).

## More to read

- [Topics](</topics>)
- [Agenda](</agenda>)
- [Subscribe](</subscribe>)
